CDA | Evidence Driven
CDA | Evidence Driven

dimethyl fumarate

Details

Files
Generic Name:
dimethyl fumarate
Project Status:
Pending
Therapeutic Area:
Multiple Sclerosis (MS)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0751-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Radiologically Isolated Syndrome (RIS).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Files

Proposed Scope View PDF
Last Updated : July 2, 2024